Skip to content

Study on the enhancement of adaptive immune response of CD4+ T cells against tuberculosis by novel immune checkpoint inhibitor antibodies

Study on the enhancement of adaptive immune response of CD4+ T cells against tuberculosis by novel immune checkpoint inhibitor antibodies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095521
Enrollment
Unknown
Registered
2025-01-08
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Pulmonary tuberculosis group :None
pulmonary tuberculosis with extrapulmonary tuberculosis group:None

Sponsors

Fuzhou Pulmonary Hospital of Fujian, Fuzhou city, Fujian Province(Fujian Provincial Tuberculosis Prevention and Treatment Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with secondary pulmonary tuberculosis and secondary pulmonary tuberculosis complicated by extrapulmonary tuberculosis dissemination (tuberculous pleurisy and extrapulmonary tuberculosis) that meet the requirements of the "WS 288-2017 Diagnosis of Pulmonary Tuberculosis". (2) Newly diagnosed patients who have not received anti-tuberculosis drug treatment before. (3) Patients who have signed the ‘Consent Form for the Use of Medical Information and Inpatient Samples for Scientific Research at the Fujian Provincial Tuberculosis Prevention and Treatment Hospital’.

Exclusion criteria

Exclusion criteria: (1) Patients with concurrent HIV infection or viral hepatitis; (2) Patients with concurrent endocrine and metabolic diseases such as diabetes, hyperthyroidism; (3) Patients with concurrent rheumatic diseases: systemic lupus erythematosus; (4) Patients with cancer or taking immunosuppressive drugs; (5) Patients with other concurrent extrapulmonary infections, chronic obstructive pulmonary disease, asthma, bronchiectasis; (6) Pregnant women or lactating women; (7) Patients with sputum or bronchoalveolar lavage fluid culture positive for non-tuberculous mycobacteria; (8) Patients who have used anti-tuberculosis drugs irrationally or irregularly for more than 1 month due to tuberculosis.

Design outcomes

Primary

MeasureTime frame
Immune cell surface markers;

Countries

China

Contacts

Public ContactLin Yujun

Fuzhou Pulmonary Hospital of Fujian, Fuzhou city, Fujian Province(Fujian Provincial Tuberculosis Prevention and Treatment Hospital)

yujunlin20212021@163.com+86 180 6513 9178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026